Wed, Oct 1, 2014, 8:42 AM EDT - U.S. Markets open in 48 mins.


% | $
Quotes you view appear here for quick access.

ACADIA Pharmaceuticals Inc. Message Board

ronaldgreen230 3 posts  |  Last Activity: Aug 8, 2014 4:24 PM Member since: Sep 6, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • ronaldgreen230 ronaldgreen230 Aug 8, 2014 4:24 PM Flag

    Strong Buy I don't belong to Stocktwits but someone who is a member should link this article there.

  • (Do the DD, Earnings Going To Be Great)
    Globe News Wire
    Kandi Announces Its JV's Sale Kandi Brand EV in the Second Quarter, a 238% Increase From the Previous Quarter
    July 14, 2014 08:17 ET |
    JINHUA, China, July 14, 2014 (GLOBE NEWSWIRE) -- Kandi Technologies Group, Inc. (the "Company" or "Kandi") (Nasdaq:KNDI), today announced that Kandi Electric Vehicles Group Co., Ltd. (the "JV Company"), which is a 50/50 joint venture between the Company and Shanghai Maple Guorun Automobile Co., Ltd., a 99% owned subsidiary of Geely Automobile Holdings Ltd., sold Kandi brand Electric Vehicles ("EVs") during second quarter of 2014, with a 238% increase from EV sales in the first quarter of 2014. Kandi expects to report its second quarter financial results on August 11, 2014.

  • 4 Biotech Stocks Where Analysts See 100% Upside, or Even Higher
    24/7 Wall Street
    By Lee Jackson August 8, 2014 8:20 am EDT
    Biotech Stocks in Which Analysts See 100% or More Upside: Arrowhead Research (NASDAQ: ARWR)
    Arrowhead Research Corp. (NASDAQ: ARWR) has dual licenses to two different biotech firms’ RNA interference (RNAi) technology and substrates. RNAi is a mechanism in cells that inhibits the expression of a specific gene and affects the production of a resulting protein. It is thought to be a method of silencing expression of disease-causing genes. Many analysts think the company may release positive Phase 2a for the drug called ARC-520, an RNAi therapeutic for the treatment of chronic hepatitis B virus infection, sometime in the third quarter.
    Deutsche Bank has a monster $45 target and rating of Buy. Jefferies also has the stock rated at Buy and a $30 target. RBC rounds out the list with another rating of Buy and a $35 target. The consensus price target for the stock is a $28.10. Shares closed Wednesday at $11.55.

24.76-0.91(-3.54%)Sep 30 4:15 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.